Kolexia
Barlesi Fabrice Pneumologie
Barlesi Fabrice
Pneumologie
Gustave-Roussy
Villejuif, France
1.5 K Activités
8.2 K Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs du poumon Carcinome pulmonaire non à petites cellules Carcinome pulmonaire à petites cellules Métastase tumorale COVID-19 Carcinomes Adénocarcinome Tumeurs du cerveau Carcinome épidermoïde

Collaborateurs

Voir plus
Besse Benjamin
Besse Benjamin
Gustave-Roussy, Villejuif, France
Moro-Sibilot Denis
Moro-Sibilot Denis
Hôpital Nord Grenoble, La Tronche, France
Mazieres Julien
Mazieres Julien
Hôpital Rangueil, Toulouse, France
Tomasini Pascale
Tomasini Pascale
Hôpital Nord Marseille, Marseille, France

Industries

Voir plus
Roche
19 collaboration(s)
Dernière en 2023
BMS
14 collaboration(s)
Dernière en 2022
Lilly
13 collaboration(s)
Dernière en 2022
MSD
10 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
Avelumab in First-line NSCLC (JAVELIN Lung 100): A Phase III, Open-label, Multicenter Trial of Avelumab (MSB0010718C) Versus Platinum-based Doublet as a First-line Treatment of Recurrent or Stage IV PD-L1+NSCLC
Essai Clinique (Emd Serono)   19 mars 2024
IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE): Official Title: A Phase II Multicenter, Open Label, Non-randomized Study of Neoadjuvant and Adjuvant Treatment With IPH5201 and Durvalumab in Patients With Resectable, Early-stage (II to IIIA) Non-Small Cell Lung Cancer (MATISSE)
Essai Clinique (Innate Pharma)   13 mars 2024
Final results of urelumab, an anti-CD137 agonist monoclonal antibody, in combination with cetuximab or nivolumab in patients with advanced solid tumors.
Journal for immunotherapy of cancer   07 mars 2024
LIBRETTO-001: A Phase 1/2 Study of Oral Selpercatinib (LOXO-292) in Patients With Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors With RET Activation (LIBRETTO-001)
Essai Clinique (Loxo Oncology, Inc.)   01 mars 2024
SUNRAY-01, A Global Pivotal Study in Participants With KRAS G12C-Mutant, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First-Line Treatment of LY3537982 and Pembrolizumab vs Placebo and Pembrolizumab in Those With PD-L1 Expression ≥50% or LY3537982 and Pembrolizumab, Pemetrexed, Platinum vs Placebo and Pembrolizumab, Pemetrexed, Platinum Regardless of PD-L1 Expression
Essai Clinique (Lilly)   27 février 2024
MELROSE: Phase 2 Study Evaluating MEchanisms of Resistance on Tumor Tissue and Liquid Biopsy in Patients With EGFR Mutated Nonpretreated Advanced Lung Cancer Receiving OSimErtinib Until and Beyond Radiological Progression : the MELROSE Trial
Essai Clinique (AstraZeneca)   26 février 2024
AcSé CRIZOTINIB : Secured Access to Crizotinib for Patients With Tumors Harboring a Genomic Alteration on One of the Biological Targets of the Drug.
Essai Clinique (Unicancer)   26 février 2024
A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100): A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Sotorasib (AMG 510) Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and Sotorasib (AMG 510) Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreaK 100)
Essai Clinique (Amgen)   22 février 2024
STK11/LKB1 alterations worsen the poor prognosis of KRAS mutated early-stage non-squamous non-small cell lung carcinoma, results based on the phase 2 IFCT TASTE trial.
Lung cancer (Amsterdam, Netherlands)   19 février 2024
Correction: Metabolomic analyses of COVID-19 patients unravel stage-dependent and prognostic biomarkers.
Cell death & disease   14 février 2024